Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1335-1338

  Rauw, J ^a   Wells, R A ^b   Chesney, A ^c   Reis, M ^c   Zhang, Liying ^c   Buckstein, Rena ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Anemia in the elderly; Bone marrow; Bone marrow diseases; Myelodysplastic syndromes (MDS); Scoring system

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW EXAMINATION; CONTROLLED STUDY; CYTOPENIA; DIAGNOSTIC ACCURACY; DISEASE DURATION; HUMAN; MAJOR CLINICAL STUDY; MEGALOCYTOSIS; MYELODYSPLASTIC SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

AGED; ANEMIA, MACROCYTIC; BONE MARROW; BONE MARROW EXAMINATION; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYDRO-LYASES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PANCYTOPENIA; PROBABILITY; PROGNOSIS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 80052092118     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.001     Document Type: Article

References (15)

1. Bennett J.M. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000, 72(2):131-133.
2. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(July (2)):419-425.
3. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(October (7)):2292-2302.
4. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., Woodman R.C. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104(October (8)):2263-2268.
5. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112(July (1)):45-52.
6. Penninx B.W., Pahor M., Woodman R.C., Guralnik J.M. Anemia in old age is associated with increased mortality and hospitalization. J Gerontol A Biol Sci Med Sci 2006, 61(May (5)):474-479.
7. Zakai N.A., Katz R., Hirsch C., Shlipak M.G., Chaves P.H., Newman A.B., et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the cardiovascular health study. Arch Intern Med 2005, 165(October (19)):2214-2220.
8. Zamboni V., Cesari M., Zuccala G., Onder G., Woodman R.C., Maraldi C., et al. Anemia and cognitive performance in hospitalized older patients: results from the GIFA study. Int J Geriatr Psychiatry 2006, 21(June (6)):529-534.
9. Chaves P.H., Ashar B., Guralnik J.M., Fried L.P. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated?. J Am Geriatr Soc. 2002, 50(July (7)):1257-1264.
10. Eisenstaedt R., Penninx B.W., Woodman R.C. Anemia in the elderly: current understanding and emerging concepts. Blood Rev 2006, 20(July (4)):213-226.
11. List A.F. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control 2008, (October (15 Suppl.)):29-39.
12. Buckstein R., Jang K., Friedlich J., Zhang L., Reis M., Chesney A., et al. Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. Leuk Res 2009, 33(October (10)):1313-1318.
13. Zweig M.H., e al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561-577.
14. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(October (14)):1456-1465.
15. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(March (3)):223-232.